
Jane E Churpek

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1436334/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Feasibility and limitations of cultured skin fibroblasts for germline genetic testing in hematologic disorders. Human Mutation, 2022, 43, 950-962.	2.5	15
2	Medical and Surgical Care of Patients With Mesothelioma and Their Relatives Carrying Germline BAP1 Mutations. Journal of Thoracic Oncology, 2022, 17, 873-889.	1.1	44
3	A Case of Isolated Myeloid Sarcoma Associated With Germline <i>EGFR</i> T790M Variant: The Importance of Recognizing Potential Germline Variants on Somatic Tumor Sequencing Panels. Journal of Hematology (Brossard, Quebec), 2022, 11, 71-76.	1.0	0
4	Distinct genetic pathways define pre-malignant versus compensatory clonal hematopoiesis in Shwachman-Diamond syndrome. Nature Communications, 2021, 12, 1334.	12.8	103
5	Approach to the diagnosis of aplastic anemia. Blood Advances, 2021, 5, 2660-2671.	5.2	31
6	Assessing the Feasibility and Limitations of Cultured Skin Fibroblasts for Germline Genetic Testing in Hematologic Disorders. Blood, 2020, 136, 35-36.	1.4	2
7	Inherited predisposition to malignant mesothelioma and overall survival following platinum chemotherapy. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 9008-9013.	7.1	108
8	Glucocorticoid receptor expression is associated with inferior overall survival independent of BRCA mutation status in ovarian cancer. International Journal of Gynecological Cancer, 2019, 29, 357-364.	2.5	15
9	Transcription factor mutations as a cause of familial myeloid neoplasms. Journal of Clinical Investigation, 2019, 129, 476-488.	8.2	47
10	Universal genetic testing for inherited susceptibility in children and adults with myelodysplastic syndrome and acute myeloid leukemia: are we there yet?. Leukemia, 2018, 32, 1482-1492.	7.2	48
11	Prognostic tumor sequencing panels frequently identify germ line variants associated with hereditary hematopoietic malignancies. Blood Advances, 2018, 2, 146-150.	5.2	83
12	Development of a Data Portal for Aggregation and Analysis of Genomics Data in Familial Platelet Disorder with Predisposition to Myeloid Malignancy - the RUNX1.DB. Blood, 2018, 132, 5241-5241.	1.4	0
13	Final Results from a Phase I Trial Combining Selinexor with High-Dose Cytarabine (HiDAC) and Mitoxantrone (Mito) for Remission Induction in Acute Myeloid Leukemia (AML). Blood, 2018, 132, 4073-4073.	1.4	0
14	Recognition of familial myeloid neoplasia in adults. Seminars in Hematology, 2017, 54, 60-68.	3.4	37
15	Old and new tools in the clinical diagnosis of inherited bone marrow failure syndromes. Hematology American Society of Hematology Education Program, 2017, 2017, 79-87.	2.5	29
16	Novel germ line DDX41 mutations define families with a lower age of MDS/AML onset and lymphoid malignancies. Blood, 2016, 127, 1017-1023.	1.4	179
17	Identifying Inherited and Acquired Genetic Factors Involved in Poor Stem Cell Mobilization and Donor-Derived Malignancy. Biology of Blood and Marrow Transplantation, 2016, 22, 2100-2103.	2.0	42
18	Brca1 deficiency causes bone marrow failure and spontaneous hematologic malignancies in mice. Blood, 2016, 127, 310-313.	1.4	39

JANE E CHURPEK

#	Article	IF	CITATIONS
19	Evaluation of Patients and Families With Concern for Predispositions to Hematologic Malignancies Within the Hereditary Hematologic Malignancy Clinic (HHMC). Clinical Lymphoma, Myeloma and Leukemia, 2016, 16, 417-428.e2.	0.4	74
20	Genomic analysis of germ line and somatic variants in familial myelodysplasia/acute myeloid leukemia. Blood, 2015, 126, 2484-2490.	1.4	207
21	Germline ETV6 mutations in familial thrombocytopenia and hematologic malignancy. Nature Genetics, 2015, 47, 180-185.	21.4	299
22	Development of a tiered and binned genetic counseling model for informed consent in the era of multiplex testing for cancer susceptibility. Genetics in Medicine, 2015, 17, 485-492.	2.4	79
23	Spontaneous Hepatic Rupture Associated With Epstein-Barr Virus Negative Aggressive Natural Killer Cell Leukemia. World Journal of Oncology, 2014, 5, 210-213.	1.5	1
24	Validation and Implementation of Targeted Capture and Sequencing for the Detection of Actionable Mutation, Copy Number Variation, and Gene Rearrangement in Clinical Cancer Specimens. Journal of Molecular Diagnostics, 2014, 16, 56-67.	2.8	234
25	The evolving challenge of therapy-related myeloid neoplasms. Best Practice and Research in Clinical Haematology, 2013, 26, 309-317.	1.7	71
26	Proposal for the clinical detection and management of patients and their family members with familial myelodysplastic syndrome/acute leukemia predisposition syndromes. Leukemia and Lymphoma, 2013, 54, 28-35.	1.3	88
27	Targeting Bone Marrow Lymphoid Niches In Acute Lymphoblastic Leukemia. Blood, 2013, 122, 1398-1398.	1.4	0
28	Heritability of Hematologic Malignancies: From Pedigrees to Genomics. Hematology/Oncology Clinics of North America, 2010, 24, 939-972.	2.2	9